Core Viewpoint - Polyrizon Ltd. has announced positive in-vitro results for its PL-16 Viral Blocker, demonstrating strong protection against H1N1 influenza through a reversible physical barrier mechanism [1][4]. Group 1: Product Efficacy - The PL-16 formulation effectively blocked infection from multiple respiratory viruses, including H1N1, maintaining high cell viability and preventing viral-induced cytopathic effects [2][4]. - The formulation exhibited robust protection without cytotoxicity, confirming both safety and efficacy [2][4]. Group 2: Mechanism of Action - The antiviral effect is due to a reversible physical interaction rather than irreversible viral inactivation, as viruses regained infectivity after the formulation was removed [3][4]. - The formulation acts as a temporary physical barrier that prevents viral particles from entering host cells [3][4]. Group 3: Future Development - Polyrizon plans to advance the PL-16 formulation through clinical studies, subject to regulatory approvals, reinforcing its commitment to innovative respiratory protection solutions [4][5]. - The company is also developing additional aspects of its Capture and Contain hydrogel technology for enhanced nasal delivery of drugs [6].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” “Company”), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including IMG-007, an anti-OX40 monoclonal antibody with multiple differentiating features, today announced management participation in fourth quarter investor conferences. 2025 Stifel Healthcare ConferenceFireside Chat: Thursday, November 13, 9:20am ESTNew York, NY Piper Sander ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Points - IMUNON, Inc. is a clinical-stage biotechnology company focused on DNA-mediated immunotherapy, currently in Phase 3 development with its lead product, IMNN-001, for advanced ovarian cancer [1][5] - The company will host a conference call on November 13, 2025, to discuss its third-quarter financial results and provide updates on its clinical development programs [1][2] Company Overview - IMUNON is advancing innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases, differentiating itself from conventional therapies [4] - The company is developing non-viral DNA technology, with two main modalities: TheraPlas for gene-based delivery of cytokines in solid tumors, and PlaCCine for gene delivery of viral antigens [4] Clinical Development - IMNN-001 is designed for localized treatment of advanced ovarian cancer and has completed multiple clinical trials, including a Phase 2 trial (OVATION 2) and is currently in a Phase 3 trial (OVATION 3) [5] - The therapy instructs the body to produce cancer-fighting molecules like interleukin-12 and interferon gamma at the tumor site [5] - The company has also completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101) [5]

Financial Performance - Revenue for Q3 2025 was $20.6 million, at the high end of the $19-$21 million guidance range[7, 8] - Gross margin for Q3 2025 was 58.4%, exceeding the guidance range of 56%-58%[7, 8] - Adjusted EBITDA for Q3 2025 was $2.0 million, compared to $1.3 million in Q3 2024[7, 8] - Cash provided by operations was $6.8 million, up from ($0.3 million) in the same period last year[7] Regional Performance - APAC revenue decreased by 19.6% year-over-year, impacted by China tariffs[9] - EMEA revenue was relatively flat, down 0.6% year-over-year, influenced by macroeconomic instability[9] - Americas revenue decreased by 4.4% year-over-year, with a recovery in Pre-Clinical driven by NIH/ACA funding[9] Outlook and Strategy - The company is focused on refinancing or repaying the existing credit agreement in Q4 2025[7] - Q4 revenue is projected to range from $22.5 million to $24.5 million[17] - Q4 gross margin is expected to range from 58% to 60%[17]

DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended September 30, 2025, on Wednesday, November 12, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title:Humacyte Third Quarter 2025 Financial Results and Corporate UpdateDate:No ...

— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data Provides Insights on Nebokitug’s Direct Macrophage-Mediated Mechanisms that Are Key to PSC Disease Progression— —All Three Presentations Have Been Designated as Posters of Distinction— TEL AVIV, Israel and WASHINGTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical sta ...

Core Insights - Avalo Therapeutics is focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases, with a key emphasis on the Phase 2 LOTUS trial for AVTX-009 targeting hidradenitis suppurativa [1][11][12] Recent Corporate Highlights and Upcoming Anticipated Milestones - Enrollment in the Phase 2 LOTUS trial of AVTX-009 has been completed, with topline data expected in mid-2026 [6][7] - Kevin Lind has been appointed to the Board of Directors, bringing extensive experience in financial and corporate strategy [6][7] - The leadership team has been expanded with key appointments in business development and human resources [6][7] Third Quarter 2025 Financial Update - Cash and short-term investments totaled approximately $112 million as of September 30, 2025, expected to fund operations into 2028 [6][7] - Research and development expenses for Q3 2025 were $13.6 million, an increase of $4.1 million from Q3 2024, primarily due to costs associated with the LOTUS trial [7][10] - General and administrative expenses were $5.6 million for Q3 2025, up $1.3 million from Q3 2024, mainly driven by stock-based compensation [7][10] - The net loss for Q3 2025 was $30.6 million, compared to a net income of $23.0 million in Q3 2024, largely due to a $47.3 million change in other expenses [7][10] - Basic and diluted net loss per share for Q3 2025 was $2.19, compared to a basic net income per share of $0.98 for Q3 2024 [7][10] About AVTX-009 - AVTX-009 is a humanized monoclonal antibody that targets interleukin-1β (IL-1β), a key pro-inflammatory cytokine involved in various autoimmune disorders [12] - The LOTUS trial is designed to evaluate the efficacy and safety of AVTX-009 in approximately 250 adults with moderate to severe hidradenitis suppurativa [13]

Core Viewpoint - 4D Molecular Therapeutics has announced an underwritten offering of 8,385,809 shares of common stock and pre-funded warrants, aiming to raise approximately $100 million before expenses [1] Group 1: Offering Details - The common stock is priced at $10.51 per share, while pre-funded warrants are priced at $10.5099 each, reflecting a slight discount due to the exercise price [1] - The offering is expected to close on November 7, 2025, pending customary closing conditions [1] - Leerink Partners, Evercore ISI, and Cantor are acting as joint book-running managers, with RBC Capital Markets as a co-manager for the offering [2] Group 2: Company Overview - 4D Molecular Therapeutics is a late-stage biotechnology company focused on disease-targeted therapeutics that aim to transform treatment paradigms [5] - The lead product candidate, 4D-150, targets blinding retinal vascular diseases and is currently in Phase 3 development for wet age-related macular degeneration and diabetic macular edema [5] - The second product candidate, 4D-710, is a genetic medicine for cystic fibrosis, demonstrating successful delivery of the CFTR transgene [5] Group 3: Regulatory Information - A registration statement for the securities has been filed with the U.S. Securities and Exchange Commission and became effective on August 15, 2023 [3] - The offering is being conducted only through a written prospectus, which can be accessed through the SEC's website [3]